Silo Pharma Inc. (NASDAQ: SILO) announced today that its wholly owned subsidiary, QwikAgents, has been accepted into Advanced Micro Devices' AMD AI Developer Program. The program provides QwikAgents with access to AMD Developer Cloud credits, AI development tools, training resources, and a global developer community, which the company expects will accelerate the development, testing, optimization, and deployment of its AI agent platform across consumer and enterprise applications.
QwikAgents is developing a platform that enables users to deploy persistent AI agents for tasks including research, content generation, scheduling, coding, and workflow automation. According to the company, participation in the AMD AI Developer Program is expected to support platform performance, agent reliability, and scalable deployment as QwikAgents expands its capabilities for individuals, developers, small businesses, and enterprise customers.
This acceptance marks a strategic move for Silo Pharma, a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Silo's therapeutic focus includes addressing underserved conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. Its portfolio includes programs like SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis, with research conducted in collaboration with leading universities and laboratories.
The AMD AI Developer Program is designed to help developers leverage AMD hardware and software to build and optimize AI applications. For QwikAgents, the program's resources could enhance the performance and scalability of its AI agent platform, potentially making it more competitive in the rapidly growing AI market. The platform's ability to handle tasks such as research and coding automation could appeal to a wide range of users, from individual developers to large enterprises seeking to improve efficiency through AI-driven workflows.
The news underscores Silo Pharma's diversification beyond biopharmaceuticals into AI technology through its subsidiary. By integrating AI capabilities, the company may be positioning itself to address broader market opportunities, though the long-term impact remains to be seen. For investors, this development signals Silo's commitment to expanding its technological portfolio, which could influence the company's valuation and growth trajectory.
For more details, the full press release is available at https://ibn.fm/313SC. Additional updates on Silo Pharma can be found in the company's newsroom at https://ibn.fm/SILO.
